SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin

Cancer Research

Volumn 74, Issue 1, 2014, Pages 298-308

  Shin, Dong Hoon ^a   Choi, Yong Joon ^a   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIRTUIN 1; SRT 1720; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; SIGNAL TRANSDUCTION; SIRTUIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892761395     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2620     Document Type: Article

References (40)

1. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
2. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99: 1441-54.
3. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790-7.
4. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68.
5. Qiu X, Brown KV, Moran Y, Chen D. Sirtuin regulation in calorie restriction. Biochim Biophys Acta 2010;1804:1576-83.
6. Cen Y, Y Youn D, A Sauve A. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications. Curr Med Chem 2011;18:1919-35.
7. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008;135:907-18.
8. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13.
9. Webster BR, Lu Z, Sack MN, Scott I. The role of sirtuins in modulating redox stressors. Free Radic Biol Med 2012;52:281-90.
10. Saunders L, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26:5489-504.
11. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006;20: 2913-21.
12. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki SI, Isono M, et al. Silent information regulator 2 (SIRT1) attenuates oxidative stressinduced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 2006;40:2175-82.
13. Yoshizaki T, Milne JC, Imamura T, Schenk S, Sonoda N, Babendure JL, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009;29:1363-74.
14. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009;284:18210-7.
15. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007;21:2644-58.
16. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008;451:583-6.
17. Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol 2009;185:203-11.
18. Byles V, Zhu L, Lovaas J, Chmilewski L, Wang J, Faller D, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012;31:4619-29.
19. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 2012;1271:10-9.
20. Jang SY, Kang HT, Hwang ES. Nicotinamide-induced mitophagy event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem 2012;287:19304-14.
21. Zhang Q, Wang SY, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, et al. Metabolic regulation of SIRT1 transcription via a HIC1: CtBP corepressor complex. Proc Natl Acad Sci U S A 2007;104:829-33.
22. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
23. Shin HW, Cho CH, Kim TY, Park JW. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1α synthesis in HT-29 colon cancer cells. Biochem Biophys Res Commun 2010;398: 205-11.
24. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010;11:213-9.
25. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283:20015-26.
26. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 2010;298:E751-E60.
27. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-5.
28. Kadenbach B, Barth J, Akgün R, Freund R, Linder D, Possekel S, et al. Regulation of mitochondrial energy generation in health and disease. Biochim Biophys Acta 1995;1271:103-9.
29. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281: 1309-11.
30. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
31. Belani CP. Chemotherapy regimens in advanced non small-cell lung cancer: recent randomized trials. Clin Lung Cancer 2000;2 Suppl 1:S7-S10.
32. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
33. Bunn P, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-100.
34. Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene 2013;120:1-12.
35. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21:266-81.
36. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010;10:819-23.
37. Chen R, Dioum EM, Hogg RT, Gerard RD, Garcia JA. Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. J Biol Chem 2011;286:13869-78.
38. Cantó C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009;20:98-105.36.
39. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1 possible role in AMP-activated protein kinase activation. J Biol Chem 2008; 283:27628-35.
40. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615-22.